PT Kalbe Farma Tbk (KLBF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Jan 16, 2023: Kalbe and its innovations, an effort to improve the pharmaceutical industry in Indonesia
Nov 28, 2022: Forsta Kalbe develop technology for the independence of local medical devices
Sep 30, 2022: Stem cell processing facility of Kalbe received a visit from the Ministry of Health, BPOM, BRIN, and KPSPS
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
PT Kalbe Farma Tbk (Kalbe) provides healthcare solutions to its customers. The company focuses on the development, manufacturing and distribution of prescription pharmaceutical products, consumer health products, nutritional products, and healthcare services. Its product portfolio comprises branded and unbranded generic drugs, nutritional products, supplements, and over-the-counter (OTC) drugs, energy drinks, and various other preventive products. Kalbe is involved in the marketing and trading of medical devices and provides distribution and logistics solutions for pharmaceutical products in Indonesia. It has overseas branches and representative offices in ASEAN countries, Nigeria, the Philippines, and Singapore. The company serves hospitals, pharmacies, and drug stores across Indonesia. Kalbe is headquartered in Jakarta, Indonesia.PT Kalbe Farma Tbk Key Recent Developments
Mar 05, 2023: Kalventis conduct the 2023 Indonesia Diabetes Leadership Summit with the Ministry of Health and PERKENIJan 16, 2023: Kalbe and its innovations, an effort to improve the pharmaceutical industry in Indonesia
Nov 28, 2022: Forsta Kalbe develop technology for the independence of local medical devices
Sep 30, 2022: Stem cell processing facility of Kalbe received a visit from the Ministry of Health, BPOM, BRIN, and KPSPS
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- PT Darya-Varia Laboratoria Tbk
- PT Dexa Medica
- PT Eisai Indonesia
- PT Infion
- PT Prodia Widyahusada Tbk
- PT Pyridam Farma Tbk
- PT Sanbe Farma
- PT Tempo Scan Pacific Tbk
- PT. Millennium Pharmacon International TBK
- PT. SOHO Industri Pharmasi